Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Rating ) has been assigned an average rating of 'Moderate Buy' from the twelve analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $18.50. Several analysts have recently weighed in on the stock.

https://www.dailypolitical.com/2023/03/06/iovance-biotherapeutics-inc-nasdaqiova-given-consensus-recommendation-of-moderate-buy-by-analysts.html

#dailypolitical